trending Market Intelligence /marketintelligence/en/news-insights/trending/ND8pVneIgkiku_xs6VEVPw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

SoftBank leads $1.1B investment in Roivant Sciences

COVID-19 Lockdown Boosted Growth Of Digital Platforms

Asia-Pacific markets improve broadband speeds despite COVID-19 impact

Simplifying The Assessment of Company Fundamental Data

China COVID-19 Trends In TV, Video


SoftBank leads $1.1B investment in Roivant Sciences

Japanese telecom and venture capital heavyweight SoftBank Group Corp. led a $1.1 billion investment in privately held biotech Roivant Sciences.

The investment, the largest in a healthcare company, is the first instance where Softbank has backed a drugmaker under its $93 billion SoftBank Vision Fund, according to London's Financial Times.

Roivant acquires late-stage drug candidates abandoned by big pharmaceutical companies due to cost cutting or corporate restructuring.

The Swiss company, which has most of its operations in the U.S., is developing about 14 drug candidates through its private and public subsidiaries.

The most advanced is a treatment for Alzheimer's by Axovant Sciences Ltd.